Literature DB >> 15128512

Improved production of heterologous proteins by a glucose repression-defective mutant of Kluyveromyces lactis.

Claudia Donnini1, Francesca Farina, Barbara Neglia, Maria Concetta Compagno, Daniela Uccelletti, Paola Goffrini, Claudio Palleschi.   

Abstract

The secreted production of heterologous proteins in Kluyveromyces lactis was studied. A glucoamylase (GAA) from the yeast Arxula adeninivorans was used as a reporter protein for the study of the secretion efficiencies of several wild-type and mutant strains of K. lactis. The expression of the reporter protein was placed under the control of the strong promoter of the glyceraldehyde-3-phosphate dehydrogenase of Saccharomyces cerevisiae. Among the laboratory strains tested, strain JA6 was the best producer of GAA. Since this strain is known to be highly sensitive to glucose repression and since this is an undesired trait for biomass-oriented applications, we examined heterologous protein production by using glucose repression-defective mutants isolated from this strain. One of them, a mutant carrying a dgr151-1 mutation, showed a significantly improved capability of producing heterologous proteins such as GAA, human serum albumin, and human interleukin-1beta compared to the parent strain. dgr151-1 is an allele of RAG5, the gene encoding the only hexokinase present in K. lactis (a homologue of S. cerevisiae HXK2). The mutation in this strain was mapped to nucleotide position +527, resulting in a change from glycine to aspartic acid within the highly conserved kinase domain. Cells carrying the dgr151-1 allele also showed a reduction in N- and O-glycosylation. Therefore, the dgr151 strain may be a promising host for the production of heterologous proteins, especially when the hyperglycosylation of recombinant proteins must be avoided.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128512      PMCID: PMC404430          DOI: 10.1128/AEM.70.5.2632-2638.2004

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  46 in total

1.  Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects.

Authors:  C E Ballou
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

Review 2.  Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis -- a review.

Authors:  G Gellissen; C P Hollenberg
Journal:  Gene       Date:  1997-04-29       Impact factor: 3.688

3.  RAG1 and RAG2: nuclear genes involved in the dependence/independence on mitochondrial respiratory function for growth on sugars.

Authors:  P Goffrini; A A Algeri; C Donnini; M Wesolowski-Louvel; I Ferrero
Journal:  Yeast       Date:  1989 Mar-Apr       Impact factor: 3.239

4.  Secretion of active anti-Ras single-chain Fv antibody by the yeasts Yarrowia lipolytica and Kluyveromyces lactis.

Authors:  Dominique Swennen; Marie-Françoise Paul; Laurence Vernis; Jean-Marie Beckerich; Alain Fournier; Claude Gaillardin
Journal:  Microbiology       Date:  2002-01       Impact factor: 2.777

5.  Inactivation of the KIPMR1 gene of Kluyveromyces lactis results in defective cell-wall morphogenesis.

Authors:  Daniela Uccelletti; Patrizia Mancini; Francesca Farina; Stefania Morrone; Claudio Palleschi
Journal:  Microbiology       Date:  1999-05       Impact factor: 2.777

6.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

7.  The hexokinase gene is required for transcriptional regulation of the glucose transporter gene RAG1 in Kluyveromyces lactis.

Authors:  C Prior; P Mamessier; H Fukuhara; X J Chen; M Wesolowski-Louvel
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

Review 8.  The dolichol pathway of N-linked glycosylation.

Authors:  P Burda; M Aebi
Journal:  Biochim Biophys Acta       Date:  1999-01-06

9.  A Saccharomyces cerevisiae mutant unable to convert glucose to glucose-6-phosphate accumulates excessive glucose in the endoplasmic reticulum due to core oligosaccharide trimming.

Authors:  Attila Miseta; Margit Tökés-Füzesi; David P Aiello; David M Bedwell
Journal:  Eukaryot Cell       Date:  2003-06

10.  Expression and secretion of recombinant ovine beta-lactoglobulin in Saccharomyces cerevisiae and Kluyveromyces lactis.

Authors:  T L Rocha; G Paterson; K Crimmins; A Boyd; L Sawyer; L A Fothergill-Gilmore
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

View more
  4 in total

1.  Secretion of human serum albumin by Kluyveromyces lactis overexpressing KlPDI1 and KlERO1.

Authors:  Tiziana Lodi; Barbara Neglia; Claudia Donnini
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

2.  Construction of a Kluyveromyces lactis ku80⁻ host strain for recombinant protein production: extracellular secretion of pectin lyase and a streptavidin-pectin lyase chimera.

Authors:  Lívia T Colombo; Júlio César C Rosa; Caio R S Bragança; Raphael P Ignacchiti; Mariana C T Alvim; Wendel B Silveira; Marisa V de Queiroz; Denise M S Bazzolli; Flávia M L Passos
Journal:  Mol Biotechnol       Date:  2014-04       Impact factor: 2.695

Review 3.  How to achieve high-level expression of microbial enzymes: strategies and perspectives.

Authors:  Long Liu; Haiquan Yang; Hyun-dong Shin; Rachel R Chen; Jianghua Li; Guocheng Du; Jian Chen
Journal:  Bioengineered       Date:  2013-04-25       Impact factor: 3.269

4.  Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.

Authors:  Marina Arnold; Vijay Durairaj; Egbert Mundt; Katja Schulze; Karin D Breunig; Sven-Erik Behrens
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.